Literature DB >> 2371770

Transcriptional activation from the long-terminal repeat of human immunodeficiency virus in vitro.

T Okamoto1, T Benter, S F Josephs, M R Sadaie, F Wong-Staal.   

Abstract

The mechanism of trans-acting regulation of transcription from the long terminal repeat (LTR) of human immunodeficiency virus (HIV) has been investigated. The roles of the cis-acting elements within HIV LTR, as well as the trans-acting factors present in HIV-infected cells, have been evaluated by an in vitro transcription system. Our observations indicate that both the sequence downstream from the CAP site of HIV LTR (located at nucleotide positions +1 to +56; called the TAR element) and the GC boxes (-77 to -45) are required for full transcriptional stimulation and that both the virus-encoded tat protein and one or more cellular factors might be involved. These results demonstrate the presence of a combinatorial regulation of HIV transcription by multiple factors, which may confer the provirus with greater flexibility in regulated viral gene expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2371770     DOI: 10.1016/0042-6822(90)90526-w

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

2.  Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.

Authors:  Ann Florence B Victoriano; Kaori Asamitsu; Yurina Hibi; Kenichi Imai; Nina G Barzaga; Takashi Okamoto
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  A novel cis-acting element that controls transcription of human immunodeficiency virus type 1 DNA, depending on cell type.

Authors:  Y Nakanishi; Y Masamune; N Kobayashi
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women.

Authors:  David N Feldman; Joseph G Feldman; Ruth Greenblatt; Kathryn Anastos; Leigh Pearce; Mardge Cohen; Stephen Gange; Suzanne Leanza; Robbie Burk
Journal:  AIDS Educ Prev       Date:  2009-06

5.  Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat.

Authors:  M Chowdhury; J P Taylor; C F Chang; J Rappaport; K Khalili
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions.

Authors:  Norio Takada; Takaomi Sanda; Hiroshi Okamoto; Jian-Ping Yang; Kaori Asamitsu; Lilen Sarol; Genjiro Kimura; Hiroaki Uranishi; Toshifumi Tetsuka; Takashi Okamoto
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Human immunodeficiency virus Tat transactivation: induction of a tissue-specific enhancer in a nonpermissive cell line.

Authors:  J Remenick; M F Radonovich; J N Brady
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Identification of a novel cell-type and context specific enhancer within the negative regulatory element of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  S K Sikder; D Mitra; J Laurence
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  A human chromosome 12-associated 83-kilodalton cellular protein specifically binds to the loop region of human immunodeficiency virus type 1 trans-activation response element RNA.

Authors:  C E Hart; M J Saltrelli; J C Galphin; G Schochetman
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Molecular characterization and heterogeneity of feline immunodeficiency virus isolates.

Authors:  N Maki; T Miyazawa; M Fukasawa; A Hasegawa; M Hayami; K Miki; T Mikami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.